[Newborn metabolic screening].

BACKGROUND Guidelines for neonatal screening for inborn errors of metabolism published by the Federal Joint Committee of physicians and health insurances in Germany include preanalytical specifications, e. g. blood collection at 36 to 72 hours of life and rapid sample transportation which is necessary with respect to those target diseases of the German program that might lead to very early metabolic decompensation. METHODS AND RESULTS Analysis of 149 854 data sets containing all necessary informations out of a total of 173 221 screening samples sent to our laboratory from April 2006 to the end of March 2007 showed significant discrepancies between the requested and the actual times recorded for blood collection. 11.5 % of samples were drawn later than required. Looking at outpatients only, 43 % of the samples were taken after 72 hours. Sample shipping was delayed in several hospitals and private practises, especially on weekends. This was the reason why 31.2 % of all samples could not be reported on within 72 hours after blood collection as required. In addition the quality of 914 samples (0.52 %) was insufficient so that a repeat sample had to be analysed. CONCLUSION In the future, as a rule, every baby should have his/her blood taken around the 48th hour, in any case between the 36th and 72nd hour of life. Moreover, sample shipping needs to be optimised in order to guarantee early diagnosis of inborn errors of metabolism. Also, more attention has to be paid to the quality of blood samples.

[1]  M. Epstein,et al.  Epimerase-deficiency galactosemia is not a binary condition. , 2006, American journal of human genetics.

[2]  S. Lafranchi,et al.  Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. , 2005, The Journal of pediatrics.

[3]  J. Valls-Solé,et al.  Characterization of tremor in phenylketonuric patients , 2005, Journal of Neurology.

[4]  M. Rosenfeld,et al.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. , 2004, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[5]  E. Naughten,et al.  The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine β-synthase deficiency , 2001, Journal of Inherited Metabolic Disease.

[6]  J. Dankert-Roelse,et al.  Early versus late diagnosis: psychological impact on parents of children with cystic fibrosis. , 2003, Pediatrics.

[7]  C. Vermeer,et al.  Bone mineral density in patients with classic galactosaemia , 2002, Archives of disease in childhood.

[8]  M. Landolt,et al.  Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. , 2002, The Journal of pediatrics.

[9]  C. Scriver.  Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. , 2002, The Journal of pediatrics.

[10]  D. Taruscio,et al.  A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991-1998). , 2002, The Journal of clinical endocrinology and metabolism.

[11]  A. Tenore,et al.  Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism. , 2002, Thyroid : official journal of the American Thyroid Association.

[12]  J. Sullivan.  Emotional outcome of adolescents and young adults with early and continuously treated phenylketonuria. , 2001, Journal of pediatric psychology.

[13]  N. Leslie,et al.  Evidence for alternate galactose oxidation in a patient with deletion of the galactose-1-phosphate uridyltransferase gene. , 2001, Molecular genetics and metabolism.

[14]  M. Kosorok,et al.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.

[15]  P. Guldberg,et al.  Mutation analysis anticipates dietary requirements in phenylketonuria , 2000, European Journal of Pediatrics.

[16]  M. Mitchell,et al.  Atypical hypothyroidism and the very low birthweight infant. , 2000, Thyroid : official journal of the American Thyroid Association.

[17]  S. Gropper,et al.  Free galactose content of fresh fruits and strained fruit and vegetable baby foods: more foods to consider for the galactose-restricted diet. , 2000, Journal of the American Dietetic Association.

[18]  H. Koot,et al.  Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism. , 2000, The Journal of pediatrics.

[19]  J. R. Simmons,et al.  Reduction of false negative results in screening of newborns for homocystinuria. , 1999, The New England journal of medicine.

[20]  G C Cunningham,et al.  Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. , 1998, Clinical chemistry.

[21]  T. Wilt,et al.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. , 1998, JAMA.

[22]  R. Parad.  Buccal cell DNA mutation analysis for diagnosis of cystic fibrosis in newborns and infants inaccessible to sweat chloride measurement. , 1998, Pediatrics.

[23]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[24]  F. Lowe,et al.  Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. , 1996, Urology.

[25]  P. Farrell,et al.  Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. , 1996, Pediatrics.

[26]  F. Richer,et al.  Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  V. Ramesh,et al.  Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. , 1993, Human molecular genetics.

[28]  J. Glorieux,et al.  Intellectual development at age 12 years of children with congenital hypothyroidism diagnosed by neonatal screening. , 1992, The Journal of pediatrics.

[29]  F. Accurso,et al.  Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. , 1991, The New England journal of medicine.

[30]  U. Bick,et al.  Functional and morphological deficits in late‐treated patients with homocystinuria: a clinical, electrophysiologic and MRI study , 1991, Acta neurologica Scandinavica.

[31]  D. Rosenblatt,et al.  Detection of heterozygotes for recessive alleles. Homocyst(e)inemia: paradigm of pitfalls in phenotypes. , 1990, American journal of medical genetics.

[32]  D. Millington,et al.  Application of fast atom bombardment with tandem mass spectrometry and liquid chromatography/mass spectrometry to the analysis of acylcarnitines in human urine, blood, and tissue. , 1989, Analytical biochemistry.

[33]  M. Tuchman,et al.  Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. , 1987, The Journal of pediatrics.

[34]  K. Pettigrew,et al.  The natural history of homocystinuria due to cystathionine beta-synthase deficiency. , 1985, American journal of human genetics.

[35]  A. Børresen,et al.  Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells. , 1985, Pediatric research.

[36]  K. Isselbacher,et al.  Galactosemia screening of newborns in Massachusetts. , 1971, The New England journal of medicine.

[37]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.